Clinical Trial: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Advanced Solid Tumor
Study Type: INTERVENTIONAL
Official Title: A Phase 1 First-in-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Soli
Brief Summary:
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
Read more